In a Science case-control analysis of 3,372,531 genotyped participants, the rare germline EGFR T790M variant was strongly associated with lung cancer, with carriers showing about 25-fold higher odds of disease (OR 25.18). The variant was not linked to 17 other cancer types or noncancerous pulmonary conditions, sharpening the case for family-history-driven genetic evaluation and potentially more personalized screening.

Why It Matters To Your Practice

• NPs and PAs are often the first clinicians to catch the clue that changes everything: a family history of lung cancer that does not fit the usual smoking-based risk story.

• This study suggests inherited risk can be powerful even for a rare variant, reinforcing your frontline role in spotting patients who may warrant deeper genetic review.

• The finding is especially relevant when patients have lung cancer in never-smokers, multiple affected relatives, or ancestry/geographic ties that may increase carrier frequency.

Clinical Benefits

• Carriers were not broadly predisposed to every cancer studied; the signal was specific to lung cancer, which can help focus counseling and referral decisions.

• The association appeared stronger in never-smokers, offering a practical reminder not to dismiss lung cancer risk when tobacco exposure is absent.

• If future evidence supports it, identifying EGFR T790M carriers could open the door to personalized CT screening at a more curable stage.

Managing Risks

• Do not overgeneralize: this was an association study, and the variant is rare, so routine population-wide testing is not established from this evidence alone.

• A positive family history should prompt careful documentation, risk assessment, and consideration of genetics referral rather than immediate assumptions about a malignant neoplasm diagnosis.

• Use extra care in counseling: patients may hear “25-fold risk” as certainty, but the key message is elevated risk, not inevitable disease.

The Bottom Line

• You are not a backup to physician decision-making here — you are often the clinician most likely to identify the inherited-risk pattern first and act on it.

• When family history points beyond smoking alone, EGFR T790M deserves a place on your radar as a high-impact clue for lung cancer risk and future screening conversations.

• Your history-taking can be the step that moves a patient from overlooked risk to earlier detection.